Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Apr;132(4):505-511.e1.
doi: 10.1016/j.anai.2023.11.016. Epub 2023 Nov 24.

Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat

Marc A Riedl  1 , Daniel Soteres  2 , J Wesley Sublett  3 , Bhavisha Desai  4 , Dianne Tomita  4 , Phil Collis  4 , Jonathan A Bernstein  5 ; APeX-S Study Investigators
Affiliations
Free article
Clinical Trial

Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat

Marc A Riedl et al. Ann Allergy Asthma Immunol. 2024 Apr.
Free article

Abstract

Background: Berotralstat, a first-line, once-daily, oral plasma kallikrein inhibitor for long-term prophylaxis of hereditary angioedema (HAE), is an effective and well-tolerated treatment option.

Objective: To summarize the safety, effectiveness, and impact on treatment satisfaction in patients who switched from injectable long-term prophylactics to oral berotralstat monotherapy (150 mg daily) at US sites in the international open-label APeX-S study.

Methods: APeX-S was an open-label, Phase II study of berotralstat conducted in 22 countries. Here, we focus on APeX-S patients enrolled at US sites who switched from injectable long-term prophylactics to berotralstat 150 mg once-daily monotherapy.

Results: A total of 34 patients discontinued lanadelumab (n = 21), subcutaneous C1 esterase inhibitor (n = 11), or intravenous C1 esterase inhibitor (n = 2) and switched to berotralstat 150 mg monotherapy. Vomiting, diarrhea, and upper respiratory tract infection were the most common adverse events (each 11.8%). Mean monthly attack rates were consistently low after the switch to berotralstat. The mean (SEM) monthly attack rate was 0.29 (0.11) at Month 1, 0.48 (0.15) at Month 6, and 0.58 (0.23) at Month 12. The median attack rate was 0 attack/mo throughout 12 months of treatment. Improvements were observed in the Treatment Satisfaction Questionnaire for Medication from baseline to Month 12 after the switch to berotralstat monotherapy, with the greatest improvements in convenience.

Conclusion: The transition from injectable prophylactic medication to berotralstat was generally well tolerated. Patients switching to berotralstat monotherapy maintained good control of their HAE symptoms and reported improved treatment satisfaction.

Trial registration: ClinicalTrials.gov Identifier: NCT03472040.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms

Associated data

LinkOut - more resources